141 related articles for article (PubMed ID: 8796904)
1. Intracellular immunization or immunotherapy for HIV infection?
Featherstone C
Mol Med Today; 1996 Jul; 2(7):271. PubMed ID: 8796904
[No Abstract] [Full Text] [Related]
2. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees.
Boyer JD; Ugen KE; Chattergoon M; Wang B; Shah A; Agadjanyan M; Bagarazzi ML; Javadian A; Carrano R; Coney L; Williams WV; Weiner DB
J Infect Dis; 1997 Dec; 176(6):1501-9. PubMed ID: 9395361
[TBL] [Abstract][Full Text] [Related]
3. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases.
Rondon IJ; Marasco WA
Annu Rev Microbiol; 1997; 51():257-83. PubMed ID: 9343351
[TBL] [Abstract][Full Text] [Related]
4. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
5. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
6. The rationale behind a vaccine based on multiple HIV antigens.
Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
8. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.
Woffendin C; Ranga U; Yang Z; Xu L; Nabel GJ
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):2889-94. PubMed ID: 8610137
[TBL] [Abstract][Full Text] [Related]
9. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains.
Duan L; Zhang H; Oakes JW; Bagasra O; Pomerantz RJ
Hum Gene Ther; 1994 Nov; 5(11):1315-24. PubMed ID: 7893803
[TBL] [Abstract][Full Text] [Related]
10. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
Calarota SA; Kjerrström A; Islam KB; Wahren B
Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
[TBL] [Abstract][Full Text] [Related]
11. An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-IT (V) (HIV-1IIIBenv/rev retroviral vector) in HIV-1-infected subjects.
Haubrich R; McCutchan JA; Holdredge R; Heiner L; Merritt J; Merchant B
Hum Gene Ther; 1995 Jul; 6(7):941-55. PubMed ID: 7578412
[No Abstract] [Full Text] [Related]
12. Intracellular immunization against HIV-1 infection of human T lymphocytes: utility of anti-rev single-chain variable fragments.
Duan L; Zhu M; Bagasra O; Pomerantz RJ
Hum Gene Ther; 1995 Dec; 6(12):1561-73. PubMed ID: 8664381
[TBL] [Abstract][Full Text] [Related]
13. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments.
Ho WZ; Lai JP; Bouhamdan M; Duan L; Pomerantz RJ; Starr SE
AIDS Res Hum Retroviruses; 1998 Nov; 14(17):1573-80. PubMed ID: 9840290
[TBL] [Abstract][Full Text] [Related]
15. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy.
Duan L; Zhu M; Ozaki I; Zhang H; Wei DL; Pomerantz RJ
Gene Ther; 1997 Jun; 4(6):533-43. PubMed ID: 9231069
[TBL] [Abstract][Full Text] [Related]
16. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
17. Transduction of CD34+ cells from the bone marrow of HIV-1-infected children: comparative marking by an RRE decoy gene and a neutral gene.
Hum Gene Ther; 2000 Jul; 11(11):1577-90. PubMed ID: 10945771
[No Abstract] [Full Text] [Related]
18. Incidence and titer of anti-rev antibody in HIV infection.
Dairaku M; Tsuchie H; Ushijima H; Aoki I; Okuda K; Honda M; Ikegami N; Hachimori K; Matsuda J; Kitamura T
AIDS; 1989 Nov; 3(11):765-6. PubMed ID: 2515884
[No Abstract] [Full Text] [Related]
19. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.
Tubiana R; Gomard E; Fleury H; Gougeon ML; Mouthon B; Picolet H; Katlama C
AIDS; 1997 May; 11(6):819-20. PubMed ID: 9143616
[No Abstract] [Full Text] [Related]
[Next] [New Search]